

, 241

PTO/SB/21 (03-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Inder the Pape	rwork Re	eduction act of 1995	no perso						on of inf	ormatio	n unless	it displa	avs a va	lid OMB	contro	l number.	
					Ap	Application Number			09/993,344			៍	?E(CE	IVE	D		
TRANSMITTAL					Fil	Filing Date 11/2				11/23	11/23/2001					1		
FORM				Fir	First Named Inventor George Jackowski						OCT	2 :	3 2003	₹Ī				
(to be used for all correspondence after initial filing)				Art	Art Unit 1646										1			
									Olga N. Chernyshev TECH CENTER 1600/					1 2900				
Tot	al Number of P	ages in	This Submission		Att	Attorney Docket Number 2132.096										\mathcal{F}^{-}		
				ENC	LOS	UF	₹ES	(Che	ck all that	t apply	()							1
	Fee Transm		Drawing(s)					After Allowance Communication to a Technology Center (TC)										
Fee Attached					Licensing-related Papers					Appeal Communication to Board of Appeals and Interferences Appeal CommunicationC					Iu			
	Amendmen	t/Reply			Petition		o Convo	art to a			쁘				ef, Repl		f)	
After Final			Petition to Convert to a Provisional Application					$ \sqcup $	Prop	rietary	ry Information							
	Affidavits/declaration(s)			Power of Attorney, Revocation Change of Correspondence Address			ess		Stati	us Lett	_etter							
			Terminal Disclaimer					Other Enclosure(s) (please Identify below):										
	Extension of Time Reduced.			Copy of				y of Int	ntil Search Report f (5) references									
								oies of (
~						CD, Number of CD(s)												
	Certified Co		Priority	Rema	irks									٠				1
	Response t																	
			to Missing Parts FR 1.52 or 1.53															
										•)						
				TURE	OF A	ιPP	LICAN	NT, A	TTORN	EY, C	OR AC	GENT]
Firm or Indivi	dual		H. Lander le & Slavin, P.A.															
Signature Lewis H. Caroler										1								
Date	Date /0/16/2005																	
			C	ERTIFI	CAT	E C	OF TR/	ANSN	IISSION	i/MAI	LING	;						<u> </u>
I hereb first cla	y certify that thi ss mail in an er	is corres nvelope	pondence is being fa addressed to: Comm	acsimile tra nissioner fo	nsmitte or Pate	ed to	the USP Washingt	PTO or di	leposited w 20231 on t	ith the his date	United S			rvice wi		ent pos	stage as	
Typed or printed Debra N. Gerstemeier									1									
Signature					/	Quen					Date	10	-16-	-200	03	1		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICA

: Jackowski et al

INVENTION

: GLYCOPROTEIN AND APOLIPOPROTEIN BIOPOLYMER MARKERS PREDICTIVE OF ALZHEIMERS DISEASE

SERIAL NUMBER

: 09/993,344

RECEIVED

FILING DATE

: November 23, 2001

OCT 2 3 2003

EXAMINER:

: Chernyshev, Olga N.

TECH CENTER 1600/2900

GROUP ART UNIT

: 1646

ATTORNEY DOCKET NO.

: 2132.096

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

De Jan

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed.

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart International patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement. A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.

Date: 10/6/2063

Respectfully submitted,

y: _____

Ferris H. Lander Registration No. 43,377

McHale & Slavin, P.A. 2855 PGA Boulevard

Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575 Facsimile: (561) 625-6572

\\Ns2\client files\2100-2199\2132 -Syn-X\2132_000096 - Glyocoprotein and Apolipoprotein\\References\Applicant's IDS References\2132.096sids2.wpd



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Re are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 09/993,344 INFORMATION DISCLOSURE Filing Date 11/23/2001 STATEMENT BY APPLICANT First Named Inventor George Jackowski Art Unit 1646 (Use as many sheets as necessary) **Examiner Name** Olga N. Chernyshev Attorney Docket Number Sheet 1 1 2132.096 of

Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-							
		number(s), publisher, city and/or country where published.					
		P. MAY, "Sulfated Glycoprotein-2: An Emerging Molecular Marker for Neurodegeneration", Annals of the New York Academy of Sciences, 679:235-244 (1993)					
		D. JENNE et al, "Molecular Structure and Functional Characterization of a Human Complement Cytolysis Inhibitor Found in Blood and Seminal Plasma: Identity to Sulfated Glycoprotein 2, a Constituent of Rat Testis Fluid", Proc. Natl. Acad. Sci. USA,					
		86:7123-7127 (September, 1989)					
		C. MULDER et al, "Genetic and Biochemical Markers for Alzheimer's Disease: Recent Developments", Ann Clin Biochem, 37:593-607 (2000)					
		E. TORNQVIST et al, "Complement and Clusterin in the Injured Nervous System", Neurobiology of Aging, 17(5):695-705 (September, 1996)					
		S. STOLTZNER et al, "Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease", American Journal of Pathology, 156(2):489-499 (February, 2000)					

Examiner	···	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this borden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.